Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Study To Evaluate The Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Selected Cognitive Domains in Clinically Stable Subjects With Schizophrenia

Trial Profile

A Randomized, Open-Label, Study To Evaluate The Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Selected Cognitive Domains in Clinically Stable Subjects With Schizophrenia

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Paliperidone (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Johnson & Johnson
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 25 Sep 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 15 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top